Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00162799
Status:
COMPLETED
Last Update Posted:
2006-06-23
First Post:
2005-09-09
Brief Title:
Efficacy Pilot Study of Triflusal in the Attenuation of Insulin Resistance in Human Obesity
Sponsor:
J Uriach and Company
Organization:
J Uriach and Company
Study Overview
Official Title:
Phase IIa Study of Triflusal in the Attenuation of Insulin Resistance in Men and Woman With Obesity
Status:
COMPLETED
Status Verified Date:
2005-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To explore the efficacy of triflusal in the attenuation of insulin resistance in human obesity Triflusal is a salicylate compound approved in several countries as antithrombotic agent antiplatelet The hypothesis is to explore if there is a reduction of obesity-induced insulin resistance by triflusal
Detailed Description:
Double-blind randomized cross-over three periods with two dose levels of triflusal placebo-controlled
Interventions treatment periods Triflusal 600 mgd 15 days Triflusal 900 mgd 15 days placebo 15 days
Washout period 30 days
Interventions treatment periods Triflusal 600 mgd 15 days Triflusal 900 mgd 15 days placebo 15 days
Washout period 30 days
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None